In 2024, Tasly Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Tasly Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 |
|---|---|---|
Total Scope 1 | 37,369.84a | 38,429.17b |
Total Scope 2 | ||
Unspecified Calculation Method | 106,327.17a | 95,737.57b |
Total Scope 3 | N/A | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 32.0928a | 31.4867b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Tasly Pharmaceutical Group amounted to 143,697.01 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Tasly Pharmaceutical Group increased by 7.1%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab
In 2024, the total Scope 1 emissions of Tasly Pharmaceutical Group were 37,369.84 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2023), Tasly Pharmaceutical Group's Scope 1 emissions decreased by 2.76%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.ab
In 2024, Tasly Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 106,327.17 tCO₂e without specifying the calculation method.a
Compared to the previous year (2023), Tasly Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) rose by 11.06% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energyab
In 2024, Tasly Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Tasly Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 37,369.84 tCO₂e and total revenues of USD 1,164 millions. This translates into an emissions intensity of 32.09 tCO₂e per millions USD.a
In 2024, Tasly Pharmaceutical Group reported a Scope 1 emissions intensity of 32.09 tCO₂e per millions USD. Compared to the peer group median of 23.6, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Tasly Pharmaceutical Group ranked 16 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Tasly Pharmaceutical Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a